卵巢癌可溶性生物标志物的新进展  

New insight of soluble biomarkers of ovarian cancer

作　　者：黄华艺[1] 

机构地区：[1]广西壮族自治区人民医院检验科,南宁530021

出　　处：《中华检验医学杂志》2016年第7期552-555,共4页Chinese Journal of Laboratory Medicine

摘　　要：卵巢癌是女性生殖系统恶性肿瘤中死亡率最高的疾病，早期症状不明显，目前缺乏敏感度和特异度高的早期诊断方法。可溶性生物标志物是指存在于体液中的生物标志物，其检测具有简便、创伤性小、花费相对低等优点，因此在肿瘤早期诊断、治疗效果监测和预后评估中有潜在价值。鉴于目前临床上用于卵巢癌诊断的可溶性生物标志物有限，其敏感度和特异度尚未满足临床要求，探索新的卵巢癌相关可溶性生物标志物是当前关注的热点。本文对目前使用的卵巢癌可溶性生物标志物的特性和诊断价值、一些潜在的新卵巢癌生物标志物以及卵巢癌标志物的合理联合检测进行讨论。Ovarian cancer has the highest mortality rate among cancers of female reproductive system.Early stage of ovarian cancer shows no signs or asymptomatic and no effective screening approach is available.Soluble biomarkers represent the biomarkers existing and can be detected in the body fluid .The detection of soluble biomarkers possess the advantages of being relatively simple , minimal invasive, and low costs, thus they are very useful in screening , therapeutic response monitoring , and prognosis prediction of cancer.However, biomarkers used for ovarian cancer diagnosis are limited , and the overall sensitivity and specificity of the tests are still below clinical satisfaction currently .Thus, seeking for new ovarian cancer soluble biomarkers is current research focus.This paper discuses the features and diagnostic value of current and potential ovarian cancer biomarkers , the reasonable combination strategy in detection of ovarian cancer biomarkers in clinical practice is also discussed .

关 键 词：卵巢肿瘤 肿瘤标记  生物学 蛋白质类 

分 类 号：R737.31[医药卫生—肿瘤] R730.43[医药卫生—临床医学]